POLYAK, Kornelia,SHU, Shaokun,BRADNER, James E.,LIN, Charles Yang
申请号：
PE0002262018
公开号：
PE10882018A1
申请日:
2016.08.10
申请国别(地区):
PE
年份:
2018
代理人:
摘要：
Referring to a combination Therapy that includes an extra terminal bromodomain inhibitor and an Activator (BET) and Protein phosphatase 2A (PP2A) is Synergistic for treating cancer.Compared with monotherapy.In addition, given an inhibitor of b-cell Lymphoma 2 (bcl-2), an inhibitor of Extra Large b-cell lymphoma (BCL XL)An inhibitor of casein kinase 2 (CK2) and \/ or an inhibitor of Mediator Complex subunit 1 (med1) in therapy.Also provided are methods for identifying a Subject that has a cancer that is resistant or are at risk of Developing resistance to the treatment with the inhibitor of bromodomain and extrTerminal (BET).Referido a una terapia combinada que comprende un inhibidor de bromodominio y extra terminal (BET) y un activador de proteina fosfatasa 2A (PP2A), siendo sinergicos para tratar el cancer, en comparacion con la monoterapia. Ademas, se administra un inhibidor de linfoma de linfocitos B-2 (Bcl- 2), un inhibidor de linfoma de linfocitos B extra grande (Bcl-xl), un inhibidor de caseina cinasa 2 (CK2) y/o un inhibidor de la subunidad 1 del complejo mediador (MED1) en la terapia. Tambien se proporcionan metodos para identificar un sujeto que tiene un cancer que es resistente o que esta en riesgo de desarrollar resistencia al tratamiento con el inhibidor de bromodominio y extra terminal (BET).
